|

Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.

RECRUITINGSponsored by Samsung Medical Center
Actively Recruiting
SponsorSamsung Medical Center
Started2024-10-22
Est. completion2025-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07068490

Summary

Despite the fact that potassium competitive acid blocker (P-CAB) has been developed for the treatment of gastric ulcer or gastroesophageal reflux disease, the efficacy and safety of P-CAB for the use of gastrointestinal (GI) protection in patients undergoing percutaneous coronary intervention (PCI) and maintaining dual antiplatelet therapy (DAPT) remains uncertain.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients who underwent PCI
* Use of either clopidogrel, prasugrel, or ticagrelor in combination with aspirin
* No use of PCAB, PPI, or an H2-receptor within the past month

Exclusion Criteria:

* Patients with low GI bleeding risk are taken on PPI
* Patients with high GI bleeding risk do not take PPI

Conditions2

Coronary Artery DiseaseHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.